Renaissance Technologies LLC Decreases Position in Personalis, Inc. $PSNL

Key Points

• Renaissance Technologies cut its Personalis stake by 83.7% in the first quarter, selling 77,794 shares and retaining 15,200 shares valued at approximately $97,000. Institutional investors collectively own 61.91% of PSNL.
• Personalis shares recently traded at $16.88, up 6.8%, near their 12-month high of $17.06. However, the company reported a quarterly loss of $0.30 per share, missing estimates, despite revenue of $22.36 million exceeding forecasts.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $14.25. Company insiders have also sold 435,032 shares worth approximately $5.6 million over the last quarter.

Renaissance Technologies LLC lessened its position in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 83.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,200 shares of the company's stock after selling 77,794 shares during the period. Renaissance Technologies LLC's holdings in Personalis were worth $97,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PSNL. Caitong International Asset Management Co. Ltd increased its position in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after acquiring an additional 1,479 shares in the last quarter. Legal & General Group Plc bought a new position in Personalis in the 2nd quarter valued at approximately $30,000. International Assets Investment Management LLC purchased a new stake in Personalis during the 4th quarter valued at $31,000. BNP Paribas Financial Markets boosted its stake in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock valued at $42,000 after purchasing an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Personalis in the 1st quarter worth $47,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Personalis Trading Up 6.8%

NASDAQ:PSNL opened at $16.88 on Friday. Personalis, Inc. has a 12 month low of $4.59 and a 12 month high of $17.06. The company has a market cap of $1.77 billion, a PE ratio of -15.49 and a beta of 2.27. The company has a 50 day simple moving average of $13.12 and a two-hundred day simple moving average of $9.62.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The firm had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Research analysts forecast that Personalis, Inc. will post -1.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PSNL shares. BTIG Research boosted their price target on Personalis from $11.00 to $16.25 and gave the stock a "buy" rating in a research note on Monday, July 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Personalis in a research report on Friday, July 17th. Morgan Stanley lifted their price objective on Personalis from $9.00 to $13.00 and gave the stock an "equal weight" rating in a report on Thursday, July 9th. Zacks Research lowered Personalis from a "hold" rating to a "strong sell" rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen cut shares of Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $14.25.

Insiders Place Their Bets

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the firm's stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares of the company's stock, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the business's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the sale, the chief financial officer owned 198,833 shares of the company's stock, valued at approximately $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 435,032 shares of company stock valued at $5,599,929. 4.20% of the stock is owned by company insiders.

About Personalis

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

Want to see what other hedge funds are holding PSNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Personalis, Inc. (NASDAQ:PSNL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source